Stock Market Reviews

OPY (Oppenheimer Holdings Inc.) News

Get the latest news, insights, and market updates on OPY (Oppenheimer Holdings Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Oppenheimer Appoints James Yoo Managing Director in Healthcare Equity Capital Markets Investment Banking
  Oppenheimer & Co. Inc. ("Oppenheimer") — a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — today announced that James Yoo has been named a Managing Director within its Healthcare Equity Capital Markets Investment Banking Group. In this role, Mr. Yoo will focus on Biotechnology Equity Capital Markets transactions.
  Oct 6, 2025 - $OPY
• Netflix stock defended at Oppenheimer amid recent underperformance
  Investing.com -- Oppenheimer analysts have reaffirmed their positive stance on Netflix, maintaining an Outperform rating and a $1,425 price target despite the stock’s recent weakness.
  Oct 3, 2025 - $OPY
• Oppenheimer Expands Custody and Prime Services (CAPS) Platform to Meet Growing Demand from Emerging Managers
  Oppenheimer & Co. Inc. — a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY) — today announced the expansion of its Custody and Prime Services (CAPS) platform, designed to better serve the evolving needs of small- and mid-sized hedge funds, investment managers, and family offices.
  Sep 30, 2025 - $OPY
• Investing in Oppenheimer Holdings (NYSE:OPY) five years ago would have delivered you a 303% gain
  When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
  Sep 21, 2025 - $OPY
• OPPENHEIMER EXPANDS GLOBAL CREDIT TEAM
  Oppenheimer Europe Limited (Oppenheimer) – a subsidiary of Oppenheimer Holdings, a leading investment bank and wealth manager (NYSE: OPY) – announced today the addition of six senior London-based professionals to its High Yield and Distressed Credit business. The group, which joins from Stifel, will play a central role in strengthening Oppenheimer's European presence and expanding the firm's ability to deliver cross-border coverage to its clients across the world.
  Sep 17, 2025 - $OPY
• RH at Risk From Higher Tariffs Disrupting Growth, Oppenheimer says
  RH (RH) is at risk that significantly higher tariffs may disrupt "top- and bottom-line" growth in th
  Sep 15, 2025 - $OPY
• Tariff-Driven Price Increases Taking Hold, With More Hikes on the Cards, Oppenheimer Study Shows
  Retail price increases tied to US President Donald Trump's tariffs are appearing to take hold, with
  Sep 12, 2025 - $OPY
• Oracle's 'Impressive' Fiscal Q1 Anchored by Record Contract Backlog and Cloud Growth, Oppenheimer Says
  Oracle's (ORCL) fiscal Q1 results showed accelerating top-line growth and record sales performance a
  Sep 10, 2025 - $OPY
• ATAI Life Sciences (ATAI) Rated as ‘Outperform’ at Oppenheimer on Psychedelic Prospects
  Atai Life Sciences (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy according to analysts. On July 29, Oppenheimer initiated coverage of the stock with an ‘Outperform’ rating and a $14 price target. The positive stance comes as the research firm views ATAI Life Sciences as a leader in the psychedelic revolution within […]
  Aug 20, 2025 - $OPY
• Oppenheimer Holdings Inc. (NYSE:OPY) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
  NYSE:OPY 1 Year Share Price vs Fair Value Explore Oppenheimer Holdings's Fair Values from the Community and select...
  Aug 10, 2025 - $OPY